Looking for a quality, under-the-radar S&P/ASX 200 Index (ASX: XJO) stock with strong forecast revenue growth?
Then you may want to check out Telix Pharmaceuticals Ltd (ASX: TLX).
Shares in the diagnostic and therapeutic product developer closed on Friday trading for $24.44. In afternoon trade on Monday, shares are swapping hands for $24.57 apiece, up 0.5%.
This sees the Telix Pharmaceuticals share price up an impressive 35.8% since this time last year, racing ahead of the 10.5% one-year gains delivered by the benchmark index.
And the ASX 200 stock looks well-positioned for another year of outperformance in FY 2026.
That's according to Chris Haynes, head of Australian equities at Equity Trustees Asset Management (courtesy of The Australian Financial Review).
"For us, quality is defined by strong management, a favourable industry structure, and a sustainable competitive advantage," Haynes said.
Here's why he's bullish on the outlook for Telix shares.
Why this ASX 200 stock could keep outperforming in FY 2026
"Telix Pharmaceuticals is not widely known, despite having an $8 billion market capitalisation," Haynes said.
"It's a commercial-stage biopharmaceutical company focused on developing and commercialising therapeutic and diagnostic radiopharmaceuticals," he added.
And the ASX 200 stock aims to minimise any side effects of its treatments.
According to Haynes:
Many existing cancer and rare disease therapies are non-selective, affecting healthy tissue and vital organs. Telix's radiopharmaceuticals are designed to deliver targeted doses of radiation via injection, regardless of where the disease is located in the body.
As for Telix's revenue outlook, Haynes said, "The company generates significant revenue in the prostate cancer diagnostics space, with strong growth forecasted."
Haynes added:
What's particularly exciting is Telix's therapy pipeline for prostate cancer and its potential expansion into other indications, such as kidney and brain cancer. Telix is a leader in the radiopharmaceutical field, and more people should know about it.
What's the latest from Telix Pharmaceuticals?
Telix reported its first-quarter results for the three months to 31 March after market close on 22 April.
And investors responded by sending the ASX 200 stock to close up 12.5% on 23 April.
Highlights from the first quarter included revenue of approximately US$186 million, up 62% year on year.
"Telix is the only company with two FDA-approved PSMA-PET5 imaging agents – Illuccix and Gozellix – enabling us to broaden patient reach and maximize choice for our customers," Telix CEO Christian Behrenbruch said following the results.
The ASX 200 stock also reaffirmed its guidance for FY 2025 on the day, targeting full-year revenue of US$770 million to US$800 million.
